Welcome to our dedicated page for Bioatla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on Bioatla stock.
BioAtla, Inc. (Nasdaq: BCAB) is a global clinical-stage biotechnology company developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, and its news flow reflects the progress of this platform. Company announcements regularly describe updates on CAB-based antibody-drug conjugates and bispecific T-cell engagers, regulatory interactions, financing arrangements, and strategic collaborations.
Recent BioAtla news has highlighted the clinical and regulatory path for ozuriftamab vedotin (Oz-V), a CAB-Platform ROR2-targeting ADC. Releases describe compelling Phase 2 data in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), FDA Fast Track Designation for certain squamous cell carcinoma of the head and neck patients, and FDA alignment on a randomized Phase 3 trial design with dual primary endpoints. Additional coverage explains a special purpose vehicle (SPV) transaction with Inversagen AI, LLC and GATC Health Corp. intended to fund a registrational Oz-V trial in OPSCC while BioAtla retains a majority ownership interest in the Oz-V asset.
News items also focus on mecbotamab vedotin (Mec-V), a CAB AXL-targeting ADC in Phase 2 development, including clinical data in treatment-refractory soft tissue sarcomas and mKRAS non-small cell lung cancer. For BA3182, a CAB EpCAM x CAB CD3 bispecific T-cell engager, BioAtla has reported preliminary Phase 1 results in metastatic adenocarcinoma patients, describing a manageable safety profile and prolonged tumor control at higher dose levels.
Investors following BCAB news will also see regular updates on financial results, cash runway, and capital structure. The company has announced Pre-Paid Advance Agreements and a Standby Equity Purchase Agreement that provide flexible equity-linked financing, as well as a special meeting of stockholders to consider approval of potential share issuances and a possible reverse stock split. Additional releases discuss Nasdaq listing compliance milestones, patent coverage, and licensing agreements such as the worldwide license to Context Therapeutics for a CAB Nectin-4 x CD3 T-cell engager.
For those tracking oncology pipelines, regulatory milestones, and financing developments in clinical-stage biotech, the BioAtla news page offers ongoing detail on how the CAB platform and its lead programs are progressing. Investors and observers can use this stream of press releases to monitor trial design decisions, data presentations at major medical congresses, partnership activity and key corporate events related to BCAB stock.
BioAtla and Context Therapeutics have entered into an exclusive worldwide license agreement for the development and commercialization of BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody. Key points include:
1. Context obtains exclusive rights to BA3362
2. BioAtla to receive $15.0 million in upfront and near-term milestones
3. Potential for up to $118.5 million in additional clinical, regulatory, and commercial milestones, plus royalties on net sales
4. Context anticipates IND filing for BA3362 in mid-2026
This agreement allows BioAtla to focus on its lead clinical CAB programs while potentially advancing BA3362 under Context's leadership. The transaction aligns with Context's strategy of building a pipeline of TCE assets through strategic in-licensing or acquisition.
BioAtla (NASDAQ: BCAB) presented promising Phase 2 trial data for ozuriftamab vedotin, a conditionally active ROR2-ADC, in treating squamous cell carcinoma of the head and neck (SCCHN) at the 2024 ESMO Annual Meeting. The trial showed an overall response rate of 32% across two dosing regimens, including an ongoing complete response. The drug demonstrated meaningful antitumor activity with manageable tolerability in heavily pretreated patients.
Key highlights include:
- 77% disease control rate
- 10 responses (1 CR, 9 PRs) among 31 evaluable patients
- Well-tolerated treatment with mostly low-grade adverse events
- FDA Fast Track Designation for R/M SCCHN treatment
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company, has announced a poster presentation at the upcoming 2024 European Society for Medical Oncology (ESMO) Annual Meeting in Barcelona, Spain. The presentation, titled 'Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN),' will be presented on September 14, 2024. The poster (Number: 868P) will showcase BioAtla's research on Conditionally Active Biologic antibody therapeutics for solid tumor treatment. Presentation materials will be available on the company's website after the event.
BioAtla (Nasdaq: BCAB), a global clinical-stage biotechnology company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024. BioAtla's management will provide a corporate update in a pre-recorded fireside chat format, which will be available on-demand starting Monday, September 9, at 7:00 a.m. ET.
BioAtla specializes in developing Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors. This conference participation offers an opportunity for investors and industry professionals to gain insights into BioAtla's latest developments and strategic direction in the field of oncology therapeutics.
BioAtla (NASDAQ: BCAB) reported Q2 2024 financial results and clinical progress. Key highlights include:
1. Ozuriftamab vedotin granted Fast Track Designation by FDA for head and neck cancer; FDA meeting anticipated in 2H 2024.
2. Evalstotug showed low incidence of immune-related adverse events; Phase 2 combination study with pembrolizumab on track for initial data in 2H 2024.
3. Mecbotamab vedotin Phase 2 trial in NSCLC showed improved overall survival in patients with KRAS mutations.
4. Cash balance projected to fund operations through Q3 2025.
5. Q2 2024 financial results: R&D expenses $16.2M (down from $31.0M in Q2 2023), G&A expenses $5.8M, net loss $21.1M, cash and equivalents $61.7M as of June 30, 2024.
BioAtla (Nasdaq: BCAB), a global clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, has announced its upcoming second quarter 2024 financial results and business highlights conference call. The event is scheduled for Thursday, August 8, 2024, at 4:30 p.m. ET.
Investors and interested parties can access the webcast through the provided link or join via phone using the dial-in numbers. The financial results press release will be available on the company's website prior to the call. A replay of the conference call will also be accessible through the Investors section of BioAtla's website.
BioAtla (Nasdaq: BCAB) hosted a virtual R&D Day highlighting updates on its clinical programs. Key findings include:
1. Mecbotamab vedotin (CAB-AXL-ADC): Showed clinical benefit in NSCLC patients with mutant KRAS variants. AXL expression ≥1% correlated with clinical benefit in heavily pretreated patients.
2. Evalstotug (CAB-CTLA-4 antibody): Demonstrated promising anti-tumor activity as monotherapy and in combination with PD-1, with a differentiated safety profile and low incidence of immune-related adverse events.
The event featured insights from key opinion leaders Dr. Edwin Yau, Dr. Omid Hamid, and Dr. Ankit Mangla, who shared positive observations on the clinical benefits and safety profiles of BioAtla's therapies.
BioAtla (Nasdaq: BCAB) has received FDA Fast Track Designation for ozuriftamab vedotin (CAB-ROR2-ADC) to treat recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). This conditionally active antibody drug conjugate has shown promising clinical activity and a manageable safety profile in treatment-refractory SCCHN patients during its Phase 2 trial. The company plans to meet with the FDA in the second half of 2024 to discuss a potential registrational trial. Fast Track Designation could expedite development and review, potentially leading to priority review if supported by clinical data at BLA submission.
BioAtla, a global clinical-stage biotechnology company specializing in CAB antibody therapeutics for solid tumors, will host a virtual R&D Day on July 25, 2024, at 10:00 AM ET. This event will provide updates on the company's clinical programs and pipeline. Attendees can register online, and a live Q&A session will follow the presentation.
BioAtla (Nasdaq: BCAB), a clinical-stage biotech firm specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, announced its participation in the Jefferies Global Healthcare Conference in New York from June 4-6, 2024.
The event will feature a fireside chat and one-on-one investor meetings on June 5, 2024, at 8:00 a.m. ET. The webcast will be available for interested parties.